Angiotensin II, which stimulates AT 1 receptors, is a brain and peripheral stress hormone. We pretreated rats with the AT 1 receptor antagonist candesartan for 13 d via sc-implanted osmotic minipumps, followed by 24-h isolation in individual metabolic cages. We measured angiotensin II receptor-type binding and mRNAs and tyrosine hydroxylase mRNA by quantitative autoradiography and in situ hybridization 
A NGIOTENSIN II (Ang II) regulates fluid and electrolyte homeostasis, hormone secretion, and the autonomic nervous system through receptors present within the brain and many peripheral tissues (1) (2) (3) . In addition, Ang II may influence other brain functions, including the central regulation of peripheral sympathetic activity and hormonal secretion from the anterior and posterior pituitary gland (2, 3) . In particular, Ang II was implicated in the response of the hypothalamic-pituitary-adrenal axis to stress. Stress increases the production of circulating Ang II (4) and the expression of Ang II receptors in brain areas such as the hypothalamic paraventricular nucleus (PVN) that are crucial for the central control of the stress reaction (2, 3, 5, 6) . Ang II stimulates CRH formation in the PVN during stress (7, 8) . Released into the hypothalamic portal system, CRH increases pituitary ACTH release. In turn, increased adrenal corticoids regulate the expression of Ang II receptors in the PVN (6, 9) . In the anterior pituitary, locally synthesized and circulating Ang II enhances the secretion of ACTH during stress (2) . In addition, Ang II has direct effects on adrenal function, stimulating aldosterone secretion from the zona glomerulosa and catecholamine release from the medulla (10 -12) . Ang II also stimulates vasopressin (AVP) formation and release in the PVN (2) . Released from the median eminence, AVP is taken through the portal circulation to participate with CRH and enhance ACTH production (13) .
There are, in mammals, two types of Ang II-binding sites, the AT 1 and AT 2 types, cloned and characterized pharmacologically (14, 15) . The AT 1 and AT 2 types have a seventransmembrane region structural topology typical of the G protein-linked superfamily of receptors, but only about 30% amino acid sequence homology (14) . The AT 1 site is the physiologically active Ang II receptor, mediating most, if not all, of the well known functions of Ang II (15) and is the receptor subtype proposed to mediate the regulation of the stress reaction by Ang II (2, 5, 16) . In rodents, there are two AT 1 receptor subtypes, AT 1A and AT 1B , encoded by two distinct genes and pharmacologically indistinguishable, sharing 95% amino acid sequence identity in their open reading frame (ORF), but only 60% nucleotide sequence homology in their 5Ј-and 3Ј-untranslated regions (UTRs) (14) . The AT 2 site is highly expressed in peripheral fetal tissues, immature brain, and rodent adrenal medulla and zona glomerulosa (3, (17) (18) (19) (20) . This site has been proposed to be involved in the regulation of growth and to cross-talk with the AT 1 receptor (3, 21, 22) . However, the experimental evidence is equivocal, and its physiological function has not yet been clarified (3, 21) .
In adult male rats only AT 1A receptors are present in brain
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areas involved in the response to stress (16, 18, 23) . In the anterior pituitary of adult rats, AT 1B receptors are the predominant isoform (23) (24) (25) . Both AT 1A and AT 1B receptors, in addition to AT 2 , are expressed in the adrenal zona glomerulosa (26) . Only AT 1A and AT 2 receptors are expressed in the adrenal medulla; the AT 2 receptor is the predominant Ang II receptor subtype (17) (18) (19) (20) .
Based on the above evidence, it was reasonable to postulate that AT 1 receptor blockade could inhibit the hormonal and sympathetic responses to stress. However, initial reports of the effects of AT 1 antagonists in stress were equivocal. When administered peripherally, the AT 1 antagonists losartan (27, 28) and irbesartan (28) did not modify (27) or only partially antagonized (28) the effects of Ang II on the brain, probably due to their limited access to brain AT 1 receptors (27, 28) . When the AT 1 receptor inhibitor losartan was administered acutely into the brain, it partially inhibited the stress-mediated catecholamine release, but did not decrease the ACTH response to stress (29) . The apparent lack of specificity of changes in AT 1 receptor expression after different stressors (5) , and the lack of effect of intracerebral administration of Ang II in AVP mRNA levels (7) suggested that Ang II, although important to modulate PVN function, might not be a major factor in the regulation of the acute hypothalamicpituitary-adrenal response to stress (5, 7, 29) .
To further clarify the role of Ang II AT 1 receptors in stress, we selected the AT 1 antagonist candesartan, an insurmountable antagonist that, when administered peripherally, readily crosses the blood-brain barrier, inhibiting not only peripheral, but also central AT 1 receptors (30). After peripheral administration of candesartan, we studied a more clinically relevant form of stress, the stress of isolation. We asked the question of how pretreatment with a peripheral and central Ang II AT 1 receptor antagonist modulated the hypothalamo-pituitary-adrenal response to isolation stress. We found that pretreatment with candesartan almost completely abolished the hormonal and sympathoadrenal responses to stress, suggesting that simultaneous antagonism of peripheral and brain AT 1 receptors could represent an advantage in the control of the stress reaction.
Materials and Methods

Animals and preparation of tissues
Wistar male rats inbred at the Centro de Investigaciones Endocrinologicas, CONICET (Buenos Aires, Argentina), or purchased from Taconic Farms, Inc. (Germantown, NY), were kept at 22 C, six animals per each 390-in. 2 cage, under a 12-h dark, 12-h light cycle with lights on at 0700 h and were given free access to normal rat diet and tap water. The NIMH (U.S.) and CONICET (Argentina) animal care and use committees approved all procedures.
At the time of the experiment, when the rats were 10 wk old and weighed between 250 and 300 g. They were anesthetized with ketamine (100 mg/kg, ip) and xylocine (10 mg/kg), and Alzet osmotic minipumps (Alza Corp., Palo Alto, CA) were implanted sc. Three groups of six animals (treated) received minipumps containing candesartan (Astra GmBH, Wedel, Germany) dissolved in 1 mol/liter sodium carbonate and further diluted in isotonic saline, to be delivered at rates of 0.1, 0.5 or 1.0 mg/kg⅐d, respectively, and these animals were later subjected to isolation stress. An additional group of six animals received osmotic minipumps filled with vehicle, at a final pH of 7.5-8.0, and these animals were also subjected to isolation stress. Control animals (referred as grouped rats) were implanted with minipumps filled with vehicle and remained grouped, six animals per cage and undisturbed, until killed as described below.
After minipump implantation the rats were kept in their cages in groups of six under standard conditions for 13 d. On d 13, the animals were individually housed in standard, 50-in. 2 plastic metabolic cages (Nalgene, Rochester, NY) that were located in the same animal room. Regular rat food and water were provided ad libitum throughout the experiment. A 24-h urine production was collected in plastic containers and stored at Ϫ20 C until use. At the end of the experiment, on d 14, the animals were killed by decapitation and the brain, pituitary gland, and adrenal glands were removed, frozen in isopentane at Ϫ30 C on dry ice, and stored at Ϫ80 C until used. For determination of ACTH and AVP, anterior and posterior pituitary glands were homogenized in 0.1 n acetic acid. For determination of catecholamines, aldosterone and corticosterone, adrenal glands were homogenized in 0.3 n perchloric acid. The clear supernatant obtained after centrifugation was stored frozen until assayed.
Tissue hormone determinations were performed in grouped, nonstressed rats, and the results were compared with those found in isolated rats treated with the AT 1 antagonist or vehicle. Thus, comparisons were made between tissue levels of catecholamines and/or hormones in isolated vs. grouped animals and of the effects of AT 1 receptor blockade during isolation. On the other hand, determination of urinary catecholamines and hormones was performed only in rats isolated in their metabolic cages, and the results represent only the effects of the AT 1 antagonist on the hormone and catecholamine secretion during isolation. We did not measure urinary excretion of catecholamines or hormones in grouped control rats. Therefore, we do not present urinary excretion data comparing grouped and isolated rats. 
Hormone determinations
Catecholamine determinations in urine and adrenal glands
Catechols in 20-l aliquots of the 24-h urine collection or in aliquots of adrenal supernatants were determined by reverse phase HPLC with electrochemical detection (31) . Sample catechols were partially purified by batch alumina extraction, separated by HPLC using a 4.6 ϫ 250-mm Zorbax Rx C 18 column (DuPont Merck Pharmaceutical Co., Wilmington, DE) and quantified amperometrically by the current produced upon exposure of the column effluent to oxidizing and then reducing potentials in series using a triple electrode system (ESA, Bedford, MA). Recovery through the alumina extraction step averaged 70 -80% for epinephrine (E) and norepinephrine (NE) and 45-55% for dihydroxyphenylglycol (DHPG). Catechol concentrations in each sample were corrected for recovery of an internal standard, dihydroxybenzylamine. DHPG levels were further corrected for differences in recovery of the internal standard and of this catechol in a mixture of external standards. The limit of detection was about 15 pg/volume assayed for each catechol.
Autoradiography of Ang II receptor subtypes
Consecutive coronal brain sections, 16 m thick, and consecutive sections from adrenal gland, 16 m thick, were cut in a cryostat, thawmounted on gelatinized slides, dehydrated overnight in a dessicator at 4 C, and kept at Ϫ80 C until used. Binding experiments were performed as described previously (32) . Sections were preincubated for 15 min in 10 mm sodium phosphate buffer, pH 7.4, containing 120 mm NaCl, 5 mm EDTA, 0.005% bacitracin, and 0.2% BSA. After preincubation, slides were transferred to fresh buffer containing 0.5 nm [
125 I]Sar 1 -Ang II (Peninsula Laboratories, Inc., Belmont, CA), iodinated by NEN Life Science Products (Boston, MA) to a specific activity of 2200 Ci/mmol to determine total binding. Nonspecific binding was determined by incubation of consecutive sections as described above in the presence of 5 m unlabeled Ang II. 
In situ hybridization of Ang II receptor subtype mRNAs
To obtain rat AT 1A , AT 1B , and AT 2 receptor-specific riboprobes, partial fragments of full-length cDNA were subcloned into the polylinker site of the pBluescript KS ϩ vector (Stratagene, La Jolla, CA). The rat (r) AT 1A cDNA was restricted with HaeIII (34) . The restriction fragment of 368 bp [from nucleotides (nt) 1317-1684] was prepared and ligated into the EcoRV site of the vector. The fragment corresponded to the 3ЈUTR of the gene with a 35-bp ORF region that did not show any identity with rAT 1B cDNA ORF. The rAT 1B cDNA was restricted with HindIII and EcoRI (35) . The restriction fragment of 398 bp (from nt 1832-2229) was prepared and ligated into the HindIII-EcoRI site of the vector. The fragment corresponded to the 3ЈUTR of the gene. The rAT 2 cDNA was restricted with XbaI and BglII (36) and the fragment of 375 bp (from nt 1478 -1852) was prepared and ligated into the XbaI-BglII site of the vector. The fragment corresponded to the 3ЈUTR of the gene. The subclones, rAT 1A -S2, rAT 1B -S1, and rAT 2 , were confirmed by DNA sequencing.
For in vitro transcription of the 35 S-labeled antisense and sense (as a control) riboprobes, the subclones were linearized with HindIII or EcoRI for the rAT 1A -S2 and rAT 1B -S1 or with XbaI or EcoRI for the rAT 2 , and then they were treated with T3 or T7 RNA polymerase, respectively. In vitro transcription was performed using the RNA labeling kit (Amersham Pharmacia Biotech) as previously described (37) . The quality of riboprobes was monitored with liquid scintillation counting and controlled by a preexperiment using adrenal gland as a positive control.
To perform in situ hybridization, sections were fixed in 4% paraformaldehyde for 10 min, acetylated for 10 min in 0.1 m triethanolamine HCl, pH 8.0, containing 0.25% acetic anhydride, dehydrated in alcohols, and air-dried. Each section was covered with 150 l hybridization buffer containing 50% formamide, 0.3 m NaCl, 2 mm EDTA, 20 mm Tris (pH 8.0), 1 ϫ Denhardt's solution, 10% dextran sulfate, 100 g/ml salmon sperm DNA, 250 g/ml yeast tRNA, 150 mm dithiothreitol, 0.1% SDS, and 40,000 cpm/l sense or antisense probe. Sections were hybridized overnight at 54 C, treated with 40 g/ml ribonuclease A (Sigma, St. Louis, MO) for 30 min, and washed in sodium chloride/sodium citrate with increasing stringency. After a final wash in 0.1 ϫ SSC (standard saline citrate) at 65 C for 60 min, sections were dehydrated through alcohols and exposed to Hyperfilm-3H (Amersham Pharmacia Biotech) along with 14 C-labeled microscales (American Radiolabeled Chemicals, Inc.) for 7 d. Films were developed as described above. The intensities of hybridization signals were quantified as nanocuries per g tissue equivalent by measuring optical film densities using the NIH Image 1.61 program after calibration with the 14 C-labeled microscales (38) . Nonspecific hybridization was analyzed using sense (control) probes.
In situ hybridization of tyrosine hydroxylase (TH) mRNA
One antisense (TH-AS) of 48-mer for the rat TH cDNA sequence localized in nt 1562-1609 (39) was synthesized (Lofstrand Laboratories Ltd., Gaithersburg, MD). Labeling was performed with a 3Ј-end labeling kit (Amersham Pharmacia Biotech) using terminal deoxynucleotidyl transferase to a specific activity of 3-4 ϫ 10 8 dpm/g. Each reaction was performed with 70 pmol oligonucleotides in the presence of 70 Ci [␣- 35 S]ATP (Amersham Pharmacia Biotech). The labeled oligonucleotides were separated from unincorporated nucleotides using MicroSpin G-25 columns (Amersham Pharmacia Biotech). In situ hybridization of rat adrenal sections and posthybridization washings were performed as previously described (38) . In situ hybridization was performed in consecutive adrenal sections, one incubated with the TH-AS oligonucleotide and another with excess unlabeled TH-AS probe (157 pmol/ml). After the washing, sections were dehydrated in alcohols containing 0.3 m ammonium acetate, air-dried, and exposed to Hyperfilm-3H (Amersham Pharmacia Biotech). The films were developed and quantified as described above by comparison with 14 C-labeled standards (American Radiolabeled Chemicals, Inc.).
Statistics
Data are the mean Ϯ sem. One-way ANOVA followed by post-hoc analysis using the Newman-Keuls multiple comparison test was used to assess the significance of differences among groups. P Ͻ 0.05 was considered statistically significant.
Results
Brain Ang II AT 1 receptors
In the PVN, isolation stress produced a significant (P Ͻ 0.03) increase in AT 1 receptor number, from 12 Ϯ 3 fmol/mg protein in control grouped rats to 25 Ϯ 3 fmol/mg protein in isolated animals (Fig. 1) . In the subfornical organ, AT 1 receptor binding showed a tendency to increase during isolation, from 50 Ϯ 7 fmol/mg protein in control grouped rats to 61 Ϯ 10 fmol/mg protein in isolated animals, but the change was not statistically significant.
We studied the effect of pretreatment with 1.0 mg/kg⅐d candesartan, as described above, on AT 1 receptor binding in the PVN after isolation stress. Predictably, AT 1 blockade eliminated the increase in AT 1 binding in the PVN produced by isolation (Fig. 1) . Binding after pretreatment with candesartan and isolation was 2 Ϯ 1 fmol/mg protein, a 90% decrease from values obtained in the PVN of isolated rats treated with vehicle (P Ͻ 0.01) and an 80% decrease in binding compared with that found in control grouped rats (P Ͻ 0.01). Pretreatment with 0.1 mg/kg⅐d candesartan significantly decreased AT 1 binding in the subfornical organ, to 15 Ϯ 3 fmol/mg protein compared with control grouped animals or isolated vehicle-treated rats (P Ͻ 0.05).
Adrenal Ang II receptor subtypes
In the zona glomerulosa, isolation stress produced a significant increase in AT 1 receptor binding and a selective increase in AT 1B receptor mRNA, without changes in AT 1A receptor mRNA (Fig. 2) . Binding to AT 2 receptors and AT 2 mRNA showed a tendency to increase in the zona glomerulosa after isolation, although the difference did not reach statistical significance (Fig. 2) . In the adrenal medulla, there was no significant change in AT 1 receptor binding after isolation (Fig. 3) . The expression of AT 1A receptor mRNA was lower during isolation compared with that in grouped controls, but the result was not statistically significant (Fig. 3) . Conversely, isolation stress produced a large significant increase in AT 2 receptor binding (Fig. 3) .
In the zona glomerulosa, administration of an AT 1 antagonist altered the expression of Ang II receptor type binding in opposite directions. Candesartan abolished the increased AT 1 expression produced by isolation stress (Fig. 2) . In addition, AT 1 receptor binding was strongly reduced to amounts much lower than those found in control nontreated grouped rats, even at low doses of the AT 1 antagonist (Fig.  2) . Candesartan also reduced the increased expression of AT 1B mRNA produced by isolation stress, although a significant reduction, to levels not different from those in control grouped rats, was found only at the highest dose of the AT 1 antagonist (Fig. 2) . AT 1A mRNA expression was also reduced by candesartan pretreatment, but the decrease was significant when compared with control grouped or vehicletreated isolated rats only when the highest dose of the AT 1 receptor antagonist was administered (Fig. 2) .
Conversely, AT 2 binding in the zona glomerulosa, which showed a tendency toward an increase during isolation (Fig.  2) , increased even further after pretreatment with the AT 1 antagonist (Fig. 2) . In addition, the highest dose of the AT 1 antagonist significantly increased the expression of AT 2 mRNA during isolation (Fig. 2) .
In the adrenal medulla, pretreatment with the AT 1 receptor antagonist decreased AT 1 binding to levels markedly lower than those observed in grouped controls or vehicletreated isolated rats (Fig. 3) . Pretreatment with candesartan did not significantly affect AT 1A mRNA expression during isolation (Fig. 3) .
Pretreatment with the AT 1 receptor antagonist eliminated the stress-related increase in AT 2 binding in the adrenal medulla (Fig. 3) , and the highest dose of candesartan reduced AT 2 binding in the adrenal medulla even further to levels lower than those observed in grouped rats (Fig. 3) . Conversely, the highest dose of the AT 1 antagonist enhanced the expression of AT 2 mRNA in the adrenal medulla to levels significantly higher than those in control grouped or vehicletreated isolated rats (Fig. 3) .
Pituitary hormones
Isolation produced significant elevations in the pituitary ACTH content (Fig. 4) and a significant reduction in the posterior pituitary AVP content (Fig. 5) . Pretreatment with the AT 1 receptor blocker completely eliminated the increase in pituitary ACTH produced by isolation stress, and this effect occurred even at the lowest dose of candesartan used (Fig. 4) . Similarly, candesartan pretreatment reversed the decrease in pituitary AVP concentrations, dose-dependently restoring the AVP content to concentrations not different from those in grouped control rats (Fig. 5) .
Adrenal hormones
After isolation, the adrenal corticosterone content was markedly elevated compared with that in grouped animals (Fig. 4) . The adrenal aldosterone content was also significantly increased after isolation compared with that in grouped control rats (Fig. 6 ). In the adrenal gland, AT 1 receptor blockade abolished the increase in adrenal corticosterone (Fig. 4) and aldosterone (Fig. 6 ) content produced by isolation.
Urinary hormones
We measured urinary hormones only in groups subjected to isolation. Pretreatment with the AT 1 receptor antagonist significantly reduced the 24-h urinary corticosterone excretion (Fig. 4) . Significant reductions in urinary corticosterone occurred after candesartan treatment at doses of 0.1 and 0.5 mg/kg⅐d (Fig. 4) . Treatment with 1.0 mg/kg⅐d candesartan reduced urinary corticosterone by 17%, but the change was not statistically significant. The urinary excretion of aldosterone was also significantly reduced after pretreatment with the AT 1 receptor antagonist at a dose of 0.5 and 1.0 mg/kg⅐d (Fig. 6) .
Treatment with the AT 1 receptor antagonist significantly decreased the 24-h urinary elimination of AVP, an effect that occurred even when the lowest doses of the antagonist were used (Fig. 5) .
Adrenal TH mRNA and catecholamines
Isolation produced significant elevations in TH mRNA in the adrenal medulla (Fig. 7) and in adrenal E and NE contents (Fig. 7) . Blockade of AT 1 receptors abolished the increase in TH mRNA produced by isolation (Fig. 7) . At the highest doses of candesartan, expression of TH mRNA showed a tendency to decrease to levels even less than those present in control grouped rats (Fig. 7) . Similarly, candesartan pretreatment eliminated the increase in adrenal E and NE concentrations produced by isolation, decreasing concentrations of both catecholamines to levels not significantly different from those in control grouped rats (Fig. 7) .
Urinary catecholamines
We determined urinary excretion of catecholamines only in animals subjected to isolation. Pretreatment with the AT 1 receptor antagonist significantly and dose-dependently reduced the urinary excretion of E and NE and that of the NE metabolite DHPG during isolation (Fig. 7) .
Discussion
Studies using a well characterized model of stress in rodents, immobilization or restraint, indicated that peripheral and brain Ang II plays a role in the response to stress (2) . We chose a more clinically relevant model of individual isolation in unfamiliar metabolic cages because it represents, for rodents, a significant emotional stress resulting from the restriction from freely regulating their exposure to novel surroundings and their access to familiar territory (40) .
We found that a relatively short (24-h) period of isolation enhanced Ang II AT 1 receptor expression in the PVN to an extent similar to the increase in AT 1 receptors that occurs during repeated immobilization stress (2, 5, 6), increased pituitary ACTH, decreased pituitary AVP, and increased adrenal corticosterone, aldosterone, catecholamines, and TH mRNA. Increased pituitary ACTH content, in association with increased adrenal corticosterone and aldosterone, can be best interpreted as evidence of increased ACTH formation in association with increased ACTH release during stress and the consequent stimulation of adrenal hormone synthesis. The increased AT 1 receptor expression in the PVN in association with the increased pituitary ACTH and adrenal corticosterone and aldosterone contents supports the hypothesis of a role for AT 1 receptors in the regulation of the enhanced hypothalamic-pituitary-adrenal response to stress and indicates that isolation produces a classical stress response.
Increased AVP release into the circulation, such as that produced by water deprivation, results in a depletion of AVP stores, leading to decreased posterior pituitary AVP content (41) . In some stress models, AVP secretion from the pituitary to the circulation also increases (42) . We interpret the decreased AVP content during isolation stress as indirect evidence of increased release, probably in response to increased AT 1 receptor stimulation (2) .
The increase in adrenomedullary mRNA for TH, the ratelimiting enzyme in catecholamine biosynthesis, in parallel with increased E and NE concentrations, indicated increased catecholamine synthesis during isolation, in agreement with previous studies demonstrating that isolation produces increased sensitivity, as determined by increased E and corticosterone, to other forms of stress (43, 44) . There were associated alterations in adrenal Ang II receptor type expression during isolation. In the zona glomerulosa, higher AT 1 receptor binding and AT 1B mRNA during stress indicated receptor up-regulation, and this correlates with increased aldosterone content. Our results support the hypothesis that in the rat, stimulation of aldosterone synthesis by Ang II is probably mediated through AT 1B receptor stimulation (45, 46) .
In rat adrenal medulla, AT 1 receptors, although few in number, mediate catecholamine secretion by Ang II (47) . However, in the medulla of isolated rats, only AT 2 receptor binding was increased, and this correlated with the increase in adrenomedullary catecholamines. Our findings suggest that rat adrenomedullary AT 2 receptor expression may play a still undetermined role in catecholamine synthesis and release during isolation (26, 48) .
We asked whether antagonism of AT 1 receptors by blocking the physiological effects of Ang II (2) could significantly affect the hormonal and sympathoadrenal response to isolation stress. Because candesartan readily crosses the bloodbrain barrier (30) , peripheral administration of the AT 1 antagonist almost completely blocked AT 1 receptor binding, not only in peripheral tissues such as anterior pituitary and adrenal gland, but also in the brain. Candesartan treatment effectively blocked peripheral and brain AT 1 binding after isolation in a manner similar to what was previously observed in control grouped rats (30) .
Chronic AT 1 receptor blockade totally abolished the increase in pituitary ACTH and adrenal corticosterone during isolation stress, probably as a result of combined AT 1 receptor blockade in the pituitary and adrenal glands and in the parvocellular region of the PVN (30) . Moreover, during isolation, AT 1 receptor blockade abolished the decrease in the posterior pituitary content of AVP. These findings can be interpreted as the result of decreased AVP release from the posterior pituitary gland during blockade of AT 1 receptors in magnocellular neurons (2) .
In the adrenal zona glomerulosa, chronic administration of the AT 1 antagonist predictably produced a marked decrease in AT 1 binding to levels even lower than those in control rats, a finding that correlated with a significant decrease in adrenal aldosterone to levels not different from those in control nonstressed rats and with a significant reduction in the urinary excretion of aldosterone during isolation. These results indicate that increased AT 1 receptor stimulation, in addition to ACTH (10) , is an important factor in the increase in aldosterone formation and release during acute stress. AT 1 blockade also suppressed the increase in AT 1B receptor mRNA that occurs during isolation, indicating that receptor blockade was not compensated by receptor transcription.
Conversely, AT 1 receptor blockade increased AT 2 receptor expression in the zona glomerulosa. This finding is intriguing because AT 2 receptor stimulation is not involved in aldosterone synthesis or release (45) . In many systems, AT 1 and AT 2 receptors have been proposed to exert opposite actions, and the receptor type expression is sometimes inversely correlated (49) . It is possible that alterations in AT 2 receptor expression could be dependent on AT 1 receptor blockade and a result of cross-talk between AT 1 and AT 2 receptors (22, 49) . However, such a reciprocal influence on receptor type expression is not universal, but, rather, is tissue specific. For example, in AT 2 gene-deficient mice, the expression of AT 1 receptors is increased in the kidney glomeruli, but not in the inner stripe of the outer medulla (49) , and in our study, binding to AT 2 receptors increased in the zona glomerulosa, but decreased in the adrenal medulla after AT 1 receptor blockade.
Pretreatment with the AT 1 receptor antagonist decreased the adrenomedullary catecholamine response to stress to levels not different from those in control grouped rats. These changes paralleled the decrease in AT 1 receptor binding expression in the adrenal medulla, supporting the hypothesis that adrenomedullary AT 1 receptor stimulation is associated with increased catecholamine formation and release. Blockade of catecholamine secretion is probably the result, in addition to AT 1 receptor antagonism in the adrenal medulla, of AT 1 receptor blockade in brain areas related to the control of peripheral sympathetic activity, i.e. the PVN and nucleus of the solitary tract (30) .
AT 2 receptor expression in the adrenal medulla also de- creased after AT 1 blockade, to levels not different from those in control grouped animals. At high candesartan concentrations, however, AT 2 receptor expression during isolation actually decreased to levels lower than control values, with a concomitant increase in AT 2 receptor mRNA expression. The mechanism and significance of these changes have not been clarified, but suggest a still undetermined role of AT 2 receptors during isolation stress and perhaps additional cross-talk between AT 1 and AT 2 receptors in the adrenal medulla (3, 22) . Pretreatment with the AT 1 receptor antagonist significantly decreased the urinary excretion of catecholamines, corticosterone, aldosterone, and AVP during isolation. Because we did not measure catecholamine and hormone urinary secretion in control, grouped animals, we cannot establish with certainty that isolation increases the urinary excretion of catecholamines, corticosterone, aldosterone, or AVP. Nevertheless, the alterations in tissue hormone and catecholamine levels during isolation are indicative of a classical stress reaction, suggesting stimulation of the hypothalamic-pituitary-adrenal axis leading to increased hormone and catecholamine release. It is logical to speculate that increased catecholamine and hormone secretion during stress could result in their increased urinary excretion. The prevention of the alterations in tissue hormone and catecholamines by pretreatment with the AT 1 antagonist parallels the decrease in urinary excretion as a result of the treatment. On the basis of these results, it is reasonable to conclude that peripheral and central AT 1 receptor blockade inhibits the hormonal and sympathoadrenal responses to stress by preventing the stress-induced increase in pituitary and adrenal hormones, an effect indirectly reflected in their decreased urinary excretion during isolation as a result of the treatment.
In conclusion, our results demonstrate that Ang II AT 1 receptor blockade is sufficient to completely abolish the hypothalamic-pituitary-adrenal response to isolation stress, strongly supporting a role for Ang II as a major stress hormone. If a blockade of pathologically enhanced responses to stress has beneficial effects, antagonism of AT 1 receptors could have a place in the therapy of stress-related disorders. It appears that a dual blockade of the peripheral and central AT 1 receptors, as reported here, may have advantages compared with selective peripheral or central blockade (27) (28) (29) . In addition, compounds that readily and insurmountably block brain as well as peripheral AT 1 receptors inhibit both the peripheral and central components of the stress response and avoid the rebound AT 1 receptor stimulation that can occur when surmountable antagonists are used (50) . Our results suggest that centrally acting, insurmountable AT 1 antagonists could be therapeutically advantageous not only in hypertension, but also for the treatment of stress-related disorders.
